AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.

Trial Details

NCT ID
NCT07038343
Phase
PHASE1 / PHASE2
Sponsor
Avenzo Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • AVZO-1418
  • Combination Agent 1
  • Combination Agent 2
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Patient must be an adult, between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life exp…
  • Patients with histologically or cytologically confirmed locally advanced/metastatic malignancies for tumor types of preferred indications:
  • o Locally advanced or metastatic epithelial solid tumors (as specified in the protocol).
  • Measurable disease as assessed by Investigator using RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →